MeSH tree: C23.550.835.900
Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). A team from Baylor College of Medicine and Texas Children's Cancer ...
Nov 27, 2024
0
37
A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient hospital quality reporting ...
Oct 21, 2024
0
26
Cytokines are regulatory proteins involved in cell proliferation, differentiation, inflammation, and hematopoiesis. An excessive immune response triggered by external viruses can lead to a severe immune reaction known as ...
Oct 10, 2024
0
41
In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and safety results similar to those ...
Oct 4, 2024
0
38
In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded ...
Sep 30, 2024
0
38
Pediatric sepsis, a major inflammatory response to trauma that can cause organ failure and tissue death, kills about 3.3 million children each year worldwide. The catastrophic overreactions to infection or injury often hit ...
Sep 24, 2024
0
70
Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old ...
Sep 5, 2024
0
69
If you're lucky enough to survive a battle with the bloodstream infection sepsis, risks of a recurrence that sends you back to hospital within a month remain high, new data shows.
Sep 2, 2024
0
39
Bryan Hsu is tackling an area of research that has long been neglected—menstrual products.
Jul 10, 2024
0
139
Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human Phase I trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, ...
Jun 12, 2024
0
47
